- Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer Mirage News
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial The Lancet
- View full coverage on Google News
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer – Mirage News
ByGoogle News
Sep 26, 2019